Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1757-2215
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin ; volume:4 ; number:1 ; day:05 ; month:12 ; year:2011 ; pages:1-11 ; date:12.2011
Journal of ovarian research ; 4, Heft 1 (05.12.2011), 1-11, 12.2011
- Creator
-
Sherman-Baust, Cheryl A.
Becker, Kevin G.
Wood III, William H.
Zhang, Yongqing
Morin, Patrice J.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/1757-2215-4-21
- URN
-
urn:nbn:de:101:1-2021082319294734799783
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:51 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Sherman-Baust, Cheryl A.
- Becker, Kevin G.
- Wood III, William H.
- Zhang, Yongqing
- Morin, Patrice J.
- SpringerLink (Online service)
Other Objects (12)
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells
Doxorubicin-induced ovarian toxicity
Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report
The synergistic mechanisms of propofol with cisplatin or doxorubicin in human ovarian cancer cells
NIPEC with Single-Dose Intraperitoneal Cisplatin and Paclitaxel in Stage III Epithelial Ovarian Cancer
Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin
Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells
No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells
Doxorubicin-induced ovarian toxicity
Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report
The synergistic mechanisms of propofol with cisplatin or doxorubicin in human ovarian cancer cells
NIPEC with Single-Dose Intraperitoneal Cisplatin and Paclitaxel in Stage III Epithelial Ovarian Cancer
Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin
Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells
No significant role for beta tubulin mutations and mismatch repair defects in ovarian cancer resistance to paclitaxel/cisplatin
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy
Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells
Doxorubicin-induced ovarian toxicity
Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report
The synergistic mechanisms of propofol with cisplatin or doxorubicin in human ovarian cancer cells
NIPEC with Single-Dose Intraperitoneal Cisplatin and Paclitaxel in Stage III Epithelial Ovarian Cancer
Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin
Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells